Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ARHGEF2
REST API REST API
Homo sapiens
ARHGEF2 is differentially expressed in 335 experiments: 138 organism parts: liver, pancreas, ... (136 more);, 208 disease states: normal, prostate carcinoma, ... (206 more);, 96 cell types 427 cell lines 48 compound treatments and 77 other conditions.
Synonyms P40, KIAA0651, GEF-H1, LFP40
Orthologs Arhgef2 (Mus musculus)   arhgef1 (Danio rerio)   ARHGEF2 (1 of 2) (Danio rerio)   ROM1 (Saccharomyces cerevisiae)   A6H6Z8_BOVIN (Bos taurus)   Arhgef2 (Rattus norvegicus)   ROM2 (Saccharomyces cerevisiae)   CG10188 (Drosophila melanogaster)   NP_001001456.1 (Xenopus laevis)   ARHG2_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, establishment of mitotic spindle orientation, cell division, microtubule binding, protein binding, apoptosis, cytoskeleton, cytoplasm, regulation of cell proliferation, intracellular, Golgi apparatus, intracellular protein transport, tight junction, metal ion binding, negative regulation of microtubule depolymerization, cell morphogenesis, actin filament organization, cell junction, regulation of Rho protein signal transduction, guanyl-nucleotide exchange factor activity, cell cycle, small GTPase mediated signal transduction, spindle, microtubule, cell projection, regulation of small GTPase mediated signal transduction, mitosis, Rho guanyl-nucleotide exchange factor activity, positive regulation of NF-kappaB transcription factor activity, negative regulation of neurogenesis, zinc ion binding, neuronal cell body, Rac GTPase binding, Rac guanyl-nucleotide exchange factor activity, Rho GTPase binding, induction of apoptosis by extracellular signals, nerve growth factor receptor signaling pathway, dendritic shaft, ruffle membrane, intracellular signal transduction
InterPro Term Pleckstrin_homology, DH-domain, Prot_Kinase_C-like_PE/DAG-bd
UniProt Accession Q92974, D3DVA5, Q5VY93, B7Z977, F5H3H5
Search EB-eye ENSG00000116584
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-3529, E-GEOD-19639
BT474
3
E-MTAB-37, E-MTAB-62, E-MEXP-440
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
PC3
2
E-MEXP-2034, E-GEOD-5258
SW480
2
E-MEXP-1014, E-MTAB-37
HL-60
1
2
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
421 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, E-GEOD-21750, ... (51 experiments)

Factor Value U/D Experiments
embryonic stem cell
2
E-GEOD-26672, E-MEXP-930
memory B cell
2
E-TABM-702, E-MEXP-2360
fibroblast
2
E-GEOD-3204, E-GEOD-3920
single positive thymocyte
1
E-GEOD-1460
centrocyte
1
E-TABM-702
nucleus pulposus
1
E-MEXP-2488
90 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (74 experiments)

Factor Value U/D Experiments
prostate carcinoma
6
E-MTAB-62, E-GEOD-3868, E-MEXP-2034, E-GEOD-7307, E-GEOD-96, ... (6 experiments)
dermatomyositis
2
E-GEOD-1551, E-MTAB-62
Duchenne muscular dystrophy
2
E-GEOD-1004, E-GEOD-3307
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
juvenile dermatomyositis
2
E-GEOD-3307, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
202 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-3720, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (32 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-TABM-868, E-GEOD-3720
glutamine
2
E-MEXP-1335, E-MEXP-941
tBHP
1
E-MEXP-2345
CNOT7+CNOT8
1
E-MEXP-2218
mercaptopurine, methotrexate
1
E-GEOD-412
ponasterone A
1
E-GEOD-3113
42 more value(s).


Age years

studied in E-TABM-783

Factor Value U/D Experiments
n/a
1
1
E-TABM-783
1
1
E-TABM-783


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-860, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, ... (9 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-MTAB-69, E-GEOD-22148, E-TABM-147, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, ... (6 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-TABM-440, E-GEOD-837, E-MEXP-1220, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-2748

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-GEOD-2466, E-MEXP-2069, ... (36 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-4525, E-GEOD-19703, E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, ... (8 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1703, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-23984, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-15799

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4271, E-GEOD-1561

Processing time: 0.552 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM